Status:
COMPLETED
Safety Study of Cancer Specific Epitope Peptides Cocktail for Cervical, GI, and Lung Tumors
Lead Sponsor:
Kyushu University
Collaborating Sponsors:
Human Genome Center, Institute of Medical Science, University of Tokyo
Conditions:
Metastatic Tumors
Eligibility:
All Genders
20-80 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the clinical safety and efficacies of cyclophosphamide combined cancer specific epitope peptides cocktail for advanced/relapsed solid tumors including GI/lung/...
Detailed Description
KOC1, TTK, CO16(URLC10), DEPDC1, MPHOSPH1 have been identified using genome-wide expression profile analysis by the use of cDNA microarray in the previous studies. The investigators have determined th...
Eligibility Criteria
Inclusion
- clinical diagnosis of unresectable or relapsed gastrointestinal, lung or cervical cancer patients
- performance status 0-1
- age between 20 and 80
- at least 4 weeks after previous therapy
- life expectancy more than 3 months
- permissible bone marrow, liver and renal function
- HLA-A2402
- no viral hepatitis, HIV or HTLV1
Exclusion
- severe underlying disease
- pregnant or lactating women
- active brain metastasis
- uncontrollable infection
- under systemic corticosteroid or immune suppressant treatment
- history of allergy to epitope peptides or IFA
Key Trial Info
Start Date :
November 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00676949
Start Date
November 1 2007
End Date
March 1 2010
Last Update
June 23 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kyushu University Hospital
Fukuoka, Fukuoka, Japan, 812-8582